An anti-CD20 extracellular antibody-drug conjugate for the treatment of B-cell malignancies

被引：0
|
作者：
Prudent, James R.
Hall, Chad A.
Marshall, David J.
Murphy, John
Harried, Scott
机构：
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.AM2016-2964
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2964
引用
收藏
页数：3
相关论文
共 50 条
  • [21] A comparison of anti-CD20 chimeric antigen receptors in targeting B-cell malignancies
    Britton, R.
    French, R.
    Glennie, M.
    [J]. IMMUNOLOGY, 2013, 140 : 65 - 65
  • [22] Nonclinical safety evaluation of STRO-001, a site-specific anti-CD74 antibody-drug conjugate for the potential treatment of B-cell malignancies
    Solis, Willy
    De Almeida, Venita
    Yu, Abigail
    Bruhns, Maureen
    Zawada, James
    Galan, Adam
    Matheny, Shannon
    Molina, Arturo
    Hallam, Trevor
    Lupher, Mark
    [J]. CANCER RESEARCH, 2018, 78 (13)
  • [23] Polatuzumab vedotin, an anti-CD79b antibody-drug conjugate for the treatment of relapsed/refractory diffuse large B-cell lymphoma
    Camus, Vincent
    Tilly, Herve
    [J]. FUTURE ONCOLOGY, 2020, 17 (02) : 127 - 136
  • [24] Subcutaneous injections of low doses of veltuzumab (humanized anti-CD20 antibody): Objective responses in B-cell malignancies
    Allen, S. L.
    Rai, K. R.
    Elstrom, R.
    Negrea, O. G.
    Farber, C. M.
    Abbasi, R.
    Teoh, N.
    Horne, H.
    Wegener, W. A.
    Goldenberg, D. M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [25] Subcutaneous Injections of Low Doses of Humanized Anti-CD20 Veltuzumab for Treatment of Indolent B-Cell Malignancies
    Negrea, O. George
    Allen, Steven L.
    Rai, Kanti R.
    Elstrom, Rebecca
    Abassi, Rashid
    Farber, Charles M.
    Teoh, Nick
    Horne, Heather
    Wegener, William A.
    Goldenberg, David M.
    [J]. BLOOD, 2009, 114 (22) : 1446 - 1446
  • [26] In vitro and in vivo targeting and therapy of an antibody-drug conjugate (IMMU-110) in B-cell malignancies
    Sapra, P
    Stein, R
    Pickett, J
    Govindan, SV
    Cardillo, TM
    Damoci, C
    Sheerin, A
    Hansen, HJ
    Horak, ID
    Griffiths, GL
    Goldenberg, DM
    [J]. BLOOD, 2004, 104 (11) : 898A - 898A
  • [27] The antibody-drug conjugate loncastuximab tesirine for the treatment of diffuse large B-cell lymphoma
    Calabretta, Eleonora
    Hamadani, Mehdi
    Zinzani, Pier Luigi
    Caimi, Paolo
    Carlo-Stella, Carmelo
    [J]. BLOOD, 2022, 140 (04) : 303 - 308
  • [28] Development of novel anti-CD19 antibody-drug conjugates for B-cell lymphoma treatment
    Li, Zhuanglin
    Wang, Mingxue
    Yao, Xuejing
    Li, Huanzhao
    Li, Shenjun
    Liu, Lina
    Yu, Deling
    Li, Xue
    Fang, Jianmin
    Huang, Changjiang
    [J]. INTERNATIONAL IMMUNOPHARMACOLOGY, 2018, 62 : 299 - 308
  • [29] A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies
    Tobinai, Kensei
    Klein, Christian
    Oya, Naoko
    Fingerle-Rowson, Gunter
    [J]. ADVANCES IN THERAPY, 2017, 34 (02) : 324 - 356
  • [30] A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies
    Kensei Tobinai
    Christian Klein
    Naoko Oya
    Günter Fingerle-Rowson
    [J]. Advances in Therapy, 2017, 34 : 324 - 356
12345